{
  "abstract": "The causal link between elevated lipoprotein A and an increased cardiovascular risk is widely acknowledged. Whilst 1 in 5 people and 1.4 billon people globally live with an elevated lipoprotein A, it is significantly under acknowledged and underutilized as a clinical non-modifiable, inherited risk factor. The Southern Health and Social Care Trust, Cardiac Rehab team have been monitoring lipoprotein A in patients 70 years and younger over the past year in both ischaemic and non-ischaemic patients referred into the service.Method Education on the role of lipoprotein A as a non-modifiable cardiovascular risk was discussed with patients, verbal consent and understanding that no active treatment is currently available was sought. Lipoprotein A was reserved as part of the routine cardiac rehab bloods on 250 patients with known ischaemic CV disease inclusive of some non-ischaemic heart failure patients.Findings Patients with an elevated lipoprotein A were much more focused at addressing their modifiable cardiovascular risk factors, e.g, LDL reduction, hypertension, waist circumference or diabetes control to reduce CV risk as much as possible in the setting of a sole or multiple non-modifiable risk factors, such as family history, gender and age.Throughout the year a pattern of approximately 1/3 of patients monitored had an elevated lipoprotein (A).Variable spread of elevated lipoprotein A results (see table 1).All 250 patients will remain on a lipoprotein A database so treatment when licensed and available can be offered.Conclusion Cardiac Rehab teams are a prime service for reviewing patient additional cardiovascular risk from elevated lipoprotein A monitoring. Throughout the past year having additional CV risk assessment has benefited and focused patients and health professionals achieve modifiable CV risk targets before discharging patients back to primary care. Thus, aiming for a reduction of future cardiovascular events for SHSCT patients and subsequently future cost.Abstract 86 Table 1 LP(a) Risk (Heart UK) Number of patients % 90 – 200 nmol/LModerate CV risk 41/250 17 200 – 400 nmol/LHigh CV risk 38/250 15 >400 nmol/LVery High CV risk 7/250 3 Abstract 86 Table 2Barriers Barrier Solution Colleague Opinion; No treatment, no point in measuring. Education on the pertinent role of lipoprotein A testing. Costly blood sample; average £12/sample - Education of fellow cardiologists and cardiology AHP’s.- Once lifetime blood sample, unlike continual blood panel monitoring associated with other cardiovascular management pathways.- £12 versus approximate treatment cost of MI; £2390/admission or the tens to hundreds of thousands of pounds associated with cerebrovascular event.- Minimal cost for maximal patient quality of life long-term in an aging population.",
  "authors": [
    {
      "affiliations": [
        "Southern Health and Social Care Trust, Newry, UK"
      ],
      "name": "H Wilson"
    },
    {
      "affiliations": [
        "Southern Health and Social Care Trust, Newry, UK"
      ],
      "name": "I Menown"
    }
  ],
  "title": "86 Is there a role for lipoprotein (A) monitoring in cardiac rehab – lets be proactive!",
  "uid": "ac6d9a9d-9958-5aa5-9492-a6986ed5191d"
}